The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo by Rusnak D W, Lackey K, Affleck K, Wood E R, Alligood K J, Rhodes N, Keith B R, Murray D M, Knight W B, Mullin R J, Gilmer T M in Molecular cancer therapeutics (2001).

[PMID: 12467226] PubMed


Discussed In Paper


Rx Annotations

No dosing information annotated.